title: Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report.
abstract: Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.
authors: Division of Pediatric Hematology/Oncology, University of Hawaii, Honolulu, HI, USA.
authors: Bruce
authors: B
authors: Shiramizu
authors: Division of Pediatric Hematology/Oncology, Medical City Children's Hospital, Dallas, TX, USA.
authors: Stanton
authors: S
authors: Goldman
authors: Department of Biostatistics, University of Nebraska, College of Public Health, Omaha, NE, USA.
authors: Lynette
authors: L
authors: Smith
authors: Division of Pediatric Hematology/Oncology, University of Hawaii, Honolulu, HI, USA.
authors: Melissa
authors: M
authors: Agsalda-Garcia
authors: Division of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, MD, USA.
authors: Paul
authors: P
authors: Galardy
authors: Department of Pathology, University of Utah, Salt Lake City, UT, USA.
authors: Sherrie L
authors: SL
authors: Perkins
authors: Section of Pediatric Hematology-Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
authors: J Kimble
authors: JK
authors: Frazer
authors: Department of Cytogenetics, University of Nebraska Medical Center, Omaha, NE, USA.
authors: Warren
authors: W
authors: Sanger
authors: Department of Biostatistics, University of Nebraska, College of Public Health, Omaha, NE, USA.
authors: James R
authors: JR
authors: Anderson
authors: Center for Global Health, NCI, NIH, DHHS, Rockville, MD, USA.
authors: Thomas G
authors: TG
authors: Gross
authors: Division of Pediatric Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
authors: Howard
authors: H
authors: Weinstein
authors: Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
authors: Lauren
authors: L
authors: Harrison
authors: Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors: Matthew J
authors: MJ
authors: Barth
authors: Istituto di Ricerca Pediatrico-Fondazione Città della Speranza-University of Padua, Padua, Italy.
authors: Lara
authors: L
authors: Mussolin
authors: Department of Pediatrics, New York Medical College, Valhalla, NY, USA.|Department of Medicine, New York Medical College, Valhalla, NY, USA.|Department of Pathology, New York Medical College, Valhalla, NY, USA.|Department of Microbiology & Immunology, New York Medical College, Valhalla, NY, USA.|Department of Cell Biology & Anatomy, New York Medical College, Valhalla, NY, USA.
authors: Mitchell S
authors: MS
authors: Cairo
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002051:Burkitt Lymphoma / Q000097:blood* / Q000188:drug therapy*; D016543:Central Nervous System Neoplasms / Q000097:blood* / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D060830:Consolidation Chemotherapy; D005260:Female; D006801:Humans; D008297:Male; D018365:Neoplasm, Residual; D010865:Pilot Projects; D060888:Real-Time Polymerase Chain Reaction
keywords: central nervous system; children; leukaemia